The short version of GHK-Cu fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-31 and is reviewed periodically as new material appears.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
| Property | Value | Notes |
|---|---|---|
| Powder storage | Minus 20 degrees Celsius, dry, dark | Desiccant used where humidity is high |
| Solution storage | Frozen, single-use aliquots | Repeated freeze-thaw cycles increase breakdown |
| Light sensitivity | Loss of intact complex under prolonged light | Amber or opaque containers reduce exposure |
| Copper assay | ICP-MS or atomic absorption spectroscopy | Reports total copper, not the fraction bound to peptide |
| Purity assay | Reversed-phase HPLC with UV or MS detection | States whether purity refers to peptide peaks or to metal content |
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
== Consistency == Various studies on a particular topic often do not address the same outcomes, making it difficult to draw clinically useful conclusions when a group of studies is looked at as a whole. The Core Outcomes in Women's Health (CROWN) Initiative is one effort to standardize outcomes.
Leaching involves the use of aqueous solutions to extract metal from metal-bearing materials. The extracting solution is called a lixiviant. The lixiviant is optimized in terms of pH, oxidation-reduction potential, presence of chelating agents, and temperature. In a simple implementation, a slurry of the pulverized ore in the lixiviant solution is filtered to yield a solution containing the metal ion(s) of interest. For example copper in its carbonate minerals such as malachite dissolve in aqueous sulfuric acid. On the other hand, copper sulfide minerals, which are more prevalent, are not amenable to hydrometallurgy, at least until they have been roasted. Hydrometallurgy is used to extract rare earths. By using chelating agents, one can selectively extract certain metals.. Some leaching reactor configurations are in-situ, heap, vat leaching, tank, and autoclave. In-situ leaching is also called "solution mining" involves pumped extracting solution into the deposit. The Beverley uranium deposit is an example of in-situ leaching. In heap leaching, crushed (and sometimes agglomerated) ore is piled in a heap on top of an impervious sheet. Leach solution is sprayed over the top of the heap and allowed to percolate downward through the heap. The heap design usually incorporates collection sumps, which allow the "pregnant" leach solution (i.e. solution with dissolved valuable metals) to be pumped for further processing.
== Current investigations == Dutasteride has been studied in combination with bicalutamide in the treatment of prostate cancer. Ongoing clinical trials are investigating whether dutasteride may be an effective treatment for premenstrual dysphoric disorder (PMDD), because dutasteride may inhibit the conversion of progesterone to allopregnanolone, a neurosteroid metabolite, which may be responsible for some of the debilitating symptoms of PMDD.
Hong Kong's EV policy, driven by the "Hong Kong Roadmap on Popularisation of Electric Vehicles," aims to achieve zero vehicular emissions before 2050. Key strategies include banning new registration of fuel-propelled private cars, including hybrids, by 2035 or earlier, expanding charging infrastructure, and offering significant, extended tax concessions such as the One-for-One Replacement Scheme (expiring 31 March 2026).
Sources: en.wikipedia.org
The National Collection of Yeast Cultures (NCYC) is a British yeast culture collection based at the Norwich Research Park in Norwich, Norfolk, United Kingdom, that currently maintains a collection of over 4400 strains and operates under the Budapest Treaty. As well as the traditional baking and brewing yeast Saccharomyces cerevisiae, this culture collection also contains hundreds of non-pathogenic yeast species. The yeasts are kept frozen under liquid nitrogen or freeze-dried in glass ampoules. To ensure the collection's safety, it is also duplicated and stored off site. Yeasts have been stored and revived successfully decades later.
Anne Ephrussi studied biology at Harvard University in the Department of Biochemistry and Molecular Biology from where she graduated in 1979. She continued to do her PhD at the Massachusetts Institute of Technology (MIT) in the group of Susumu Tonegawa where she received her doctoral degree in 1985. Ephrussi performed postdoctoral research at Harvard University in the lab of Thomas Maniatis from 1986 to 1989 and at the Whitehead Institute for Biomedical Research with Ruth Lehmann from 1989 to 1992. Since 1992, Anne Ephrussi has been a group leader at the European Molecular Biology Laboratory (EMBL). She became the head of EMBL International Centre for Advanced Training in 2005. She served as Associate Dean (1999 - 2005) and Dean (2005 - 2008) of Graduate Studies of the EMBL International PhD program and as head of the developmental biology unit (2007-2021). She is part of numerous international Scientific Advisory Boards and Panels, organizes international conferences and scientific meetings and evaluates research grant and fellowship applications for a variety of renowned funding bodies.
== Radiation == The weak beta emission is stopped by the walls of laboratory glassware. Soft X-rays are emitted when the beta particles are stopped, but as long as the body is kept more than 30 cm away these should pose no problem. The primary hazard when working with technetium is inhalation of dust; such radioactive contamination in the lungs can pose a significant cancer risk.
== Biochemical structure == Kex2 was first purified and characterized by Charles Brenner and Robert Fuller in 1992. The Kex2 crystal structure was solved by a group led by Dagmar Ringe, Robert Fuller and Gregory Petsko. That of Furin was determined by a group led by Manual Than and Wolfram Bode. The key features of Kex2 and Furin are a subtilisin-related catalytic domain, a specificity pocket that requires the amino acid amino terminal to the scissile bond to be arginine for rapid acylation, and a P-domain carboxy-terminal to the subtilisin domain, which is required for biosynthesis.
In late 1918, Poles hoping for a sovereign Poland started serious preparations for an uprising after Wilhelm II's abdication on 9 November 1918, which marked the end of the German Empire. The monarchy was replaced by the Weimar Republic. The uprising broke out on 27 December 1918 in Poznań, after a patriotic speech by Ignacy Paderewski, the famous pianist, who would become the Polish prime minister in 1919, with 2,000 men serving in the Guard and Security Service rising up in the city. The insurrectionist forces consisted of members of the Polish Military Organization, who formed the Straż Obywatelska (Citizen's Guard), later renamed as Straż Ludowa (People's Guard), which included many volunteers, who were mainly veterans of World War I. The first contingent to reach the Bazar Hotel, from where the uprising was initiated, was a 100-strong force from wildecka kompania Straży Ludowej (Wilda's People's Guard) led by Antoni Wysocki. The ruling body was the Naczelna Rada Ludowa (Supreme People's Council). Initially, the members of the council, including Captain Stanisław Taczak and General Józef Dowbor-Muśnicki were against the uprising, but they changed their minds in support of the insurrection on 9 January 1919. The timing was advantageous for the insurrectionists since between late 1918 and early 1919, internal conflict had weakened Germany, and many of its soldiers and sailors engaged in mutinous actions against the state. Demoralized by the signing of the armistice on 11 November 1918, the new German government was further embroiled in subduing the German Revolution.
Sources: en.wikipedia.org
The colour depends on copper held in a specific coordination environment. When the complex dissociates or the peptide is cleaved, that environment changes and the visible absorption weakens.
Frozen solutions are generally less stable than dry powder, and repeated thawing accelerates breakdown. Storage temperature, concentration and buffer composition all shift the rate, so no single figure applies to every preparation.
Chromatography separates and quantifies peptide species but does not report metal content. A separate elemental measurement is needed to show how much copper is present.
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.